Risk and Reward in the Orphan Drug Industry
© 2019 Portfolio Management Research. All rights reserved. Thanks to a combination of scientific advances and economic incentives, the development of therapeutics to treat rare or orphan diseases has grown dramatically in recent years. With the advent of Food and Drug Administration–approved gene th...
Main Authors: | Lo, Andrew W, Thakor, Richard T |
---|---|
Format: | Article |
Language: | English |
Published: |
Pageant Media US
2021
|
Online Access: | https://hdl.handle.net/1721.1/134802 |
Similar Items
-
Risk and Reward in the Orphan Drug Industry
by: Lo, Andrew W, et al.
Published: (2022) -
Financing drug discovery for orphan diseases
by: Gromatzky, Austin A., et al.
Published: (2014) -
Mitaplatin, a Potent Fusion of Cisplatin and the Orphan Drug Dichloroacetate
by: Lippard, Stephen J., et al.
Published: (2011) -
Expediting treatments in the 21st century: orphan drugs and accelerated approvals
by: Domike, Reuben, et al.
Published: (2024) -
Raya Cheer For Orphans
by: Sunday Star,
Published: (2008)